Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ecora agress to sell Dugbe Gold Project royalty

(Sharecast News) - Ecora Resources announced on Tuesday that it has agreed to sell its 2% net smelter return royalty over the Dugbe Gold Project in Liberia for up to $20m, enabling it to unlock value from a non-core asset and accelerate debt reduction. The London-listed firm said the deal, with a subsidiary of Elemental Altus Royalties Corporation, included an upfront cash payment of $16.5m and contingent payments of up to $3.5m, linked to the start of construction and commercial production.

It said the contingent consideration would also be payable in full if the project were built to a smaller scale than outlined in the June 2022 feasibility study after cumulative production reached 150,000 ounces of gold.

Ecora acquired the Dugbe royalty in 2012, with a carrying value of $5.9m as of 31 December 2024.

Completion of the transaction was expected in the coming days.

"The transaction unlocks value from a development stage asset in a non-core commodity and will enable us to accelerate the group's deleveraging, as well as providing further flexibility to acquire cash generative royalties within our targeted commodity basket in time," said chief executive Marc Bishop Lafleche.

"The transaction highlights the substantial value within Ecora's wider royalty portfolio outside the core producing assets."

At 1226 BST, shares in Ecora Resources were up 4.08% at 76.39p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.